Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.56 SEK | +0.63% |
|
-4.88% | -17.23% |
05-15 | Iconovo AB Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments | CI |
05-06 | Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler | MT |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.23% | 14.45M | - | ||
+10.45% | 2.3B | - | A- | |
+20.74% | 2.3B | B | ||
-49.67% | 2.23B | B- | ||
-32.99% | 2.01B | C+ | ||
+20.00% | 1.82B | B | ||
-17.93% | 1.73B | - | ||
+6.41% | 1.33B | - | ||
+18.74% | 1.27B | B | ||
+23.24% | 1.24B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- ICO Stock
- Ratings Iconovo AB